Long-term inhaled treprostinil for PH-ILD: INCREASE open-label extension study.

Aaron B WaxmanRicardo Restrepo-JaramilloThenappan ThenappanPeter EngelAbubakr BajwaAshwin RavichandranJeremy FeldmanAmy Hajari CaseVictor TapsonPeter SmithChunqin DengEric ShenSteven D Nathan

Published in: The European respiratory journal (2023)

These results support the long-term safety and efficacy of inhaled treprostinil in patients with PH-ILD and are consistent with the results observed in the INCREASE RCT.

Keyphrases

interstitial lung disease
pulmonary arterial hypertension
open label
cystic fibrosis
clinical trial
systemic sclerosis
rheumatoid arthritis
randomized controlled trial
squamous cell carcinoma
study protocol
radiation therapy
phase ii study